Triple

T12385396
Position Surface form Disambiguated ID Type / Status
Subject Hal V. Barron E295849 entity
Predicate employer P7 FINISHED
Object Genentech E7901 NE FINISHED

How this triple was built (2 steps)

Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.

NER Named-entity recognition gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: Genentech | Statement: [Hal V. Barron, employer, Genentech]
NED1 Entity disambiguation (via context triple) gpt-5-mini-2025-08-07
Target entity: Genentech
Context triple: [Hal V. Barron, employer, Genentech]
  • A. Genentech chosen
    Genentech is a pioneering American biotechnology company known for developing groundbreaking therapies and being one of the first firms to apply genetic engineering to medicine.
  • B. Amgen
    Amgen is a leading American biopharmaceutical company known for developing innovative therapies in areas such as oncology, nephrology, and inflammatory diseases.
  • C. Janssen Biotech
    Janssen Biotech is a biopharmaceutical company known for developing and manufacturing innovative biologic therapies, including the blockbuster monoclonal antibody Remicade.
  • D. Genmab
    Genmab is a Danish biotechnology company specializing in the development of antibody-based cancer therapies.
  • E. Novartis
    Novartis is a global Swiss-based pharmaceutical company known for developing innovative medicines across a wide range of therapeutic areas.
  • F. None of above.
  • G. Unsure - the case is ambiguous/there is not enough information to decide.

Provenance (3 batches)

The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.

Step Stage Batch ID Status When
creating Elicitation batch_69d6ad9e653c8190b1473c860ee53dae completed April 8, 2026, 7:33 p.m.
NER Named-entity recognition batch_69d93fbd489c819098233a111442762e completed April 10, 2026, 6:21 p.m.
NED1 Entity disambiguation (via context triple) batch_69f62ac939bc819081629b9eef20c4e7 completed May 2, 2026, 4:48 p.m.
Created at: April 8, 2026, 9:54 p.m.